Detail Aid. I was the lead art director for the LETAIRIS brand for three years at Kane & Finkel. LETAIRIS is a PAH drug from Gilead Sciences. It is a "black box drug." That is to say, it carries the FDA's most stringent warning and is highly controlled. This means that every new communication from LETAIRIS has to be viewed and second guessed by dozens and dozens of eyes. The conceptual options, as well as imagery, were constrained by regulation. This "detail aid" (directed to physicians) includes long disclaimers and warnings. Type sizes, weights and even the use of contrasting colors had to be vetted by the manufacturer's internal legal team as well as the FDA.